文献速递造血干细胞移植与细胞治疗贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

成人范可尼贫血患者的移植结果

Transplant results in adults with Fanconi anaemia.
PubMed 文献 · Br J Haematol · 2017-11-02

该研究回顾性分析了1991至2014年间接受移植的199例成人范可尼贫血患者,中位诊断年龄16岁、移植年龄23岁;96个月非复发死亡率为56%,总生存率为34%,且随移植年代更新而改善;2000年后移植者36个月生存率达84%。

要点

  • 成人范可尼贫血移植后96个月总生存率34%,非复发死亡率56%。
  • 2000年后移植者36个月生存率84%,与使用氟达拉滨及同胞供者相关。
  • 移植时存在克隆性疾病对生存无显著影响。

核心结论

  • 成人范可尼贫血患者移植后远期生存仍不理想,但2000年后移植者生存改善,与使用氟达拉滨及同胞或匹配非同胞供者相关。

研究设计与样本

  • 回顾性分析1991年至2014年间接受移植的199例成人范可尼贫血患者,中位随访58个月。

主要发现

  • 移植时54%患者有骨髓衰竭,46%有克隆性疾病(34%骨髓增生异常,12%急性白血病)。
  • 植入率82%(95%CI 76-87%),急性移植物抗宿主病II-IV度发生率22%(95%CI 16-28%),96个月慢性移植物抗宿主病发生率26%(95%CI 20-33%)。
  • 96个月非复发死亡率为56%,总生存率为34%,随更近期的移植而改善。
  • 2000年后移植者36个月生存率为84%,使用同胞骨髓及含氟达拉滨的预处理方案。
  • 主要死亡原因为感染(37%)、移植物抗宿主病(24%)和器官衰竭(12%)。

关键数值与推荐

  • 多因素分析中与改善结局相关的因素为使用氟达拉滨及同胞或匹配非同胞供者。
  • 移植时存在克隆性疾病对生存无显著影响。
  • 131例可评估患者中15例报告了第二肿瘤。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The outcomes of adult patients transplanted for Fanconi anaemia (FA) have not been well described. We retrospectively analysed 199 adult patients with FA transplanted between 1991 and 2014. Patients were a median of 16 years of age when diagnosed with FA, and underwent transplantation at a median age of 23 years. Time between diagnosis and transplant was shortest (median 2 years) in those patients who had a human leucocyte antigen identical sibling donor. Fifty four percent of patients had bone marrow (BM) failure at transplantation and 46% had clonal disease (34% myelodysplasia, 12% acute leukaemia). BM was the main stem cell source, the conditioning regimen included cyclophosphamide in 96% of cases and fludarabine in 64%. Engraftment occurred in 82% (95% confidence interval [CI] 76-87%), acute graft-versus-host disease (GvHD) grade II-IV in 22% (95% CI 16-28%) and the incidence of chronic GvHD at 96 months was 26% (95% CI 20-33). Non-relapse mortality at 96 months was 56% with an overall survival of 34%, which improved with more recent transplants. Median follow-up was 58 months. Patients transplanted after 2000 had improved survival (84% at 36 months), using BM from an identical sibling and fludarabine in the conditioning regimen. Factors associated with improved outcome in multivariate analysis were use of fludarabine and an identical sibling or matched non-sibling donor. Main causes of death were infection (37%), GvHD (24%) and organ failure (12%). The presence of clonal disease at transplant did not significant impact on survival. Secondary malignancies were reported in 15 of 131 evaluable patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bierings M, Bonfim C, Peffault De Latour R, et al. Transplant results in adults with Fanconi anaemia. Br J Haematol. 2017. PMID: 29094350. doi:10.1111/bjh.15006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。